vasamed Announces Shipment of First Orders for Its AcQtrac(TM) ICG System
August 31 2005 - 8:03PM
PR Newswire (US)
European and U.S. Distributors in Place to Address $2B Market
Opportunity MINNEAPOLIS, Aug. 31 /PRNewswire-FirstCall/ -- vasamed
(OTC:OPTL) (BULLETIN BOARD: OPTL) , a leader in non-invasive,
hemodynamic assessment technology, announced today that it has made
initial customer shipments worldwide for its new AcQtrac(TM)
Impedance Cardiography (ICG) Noninvasive Hemodynamic Assessment
System. AcQtrac ICG is the newest generation of noninvasive
solutions that assess cardiovascular functioning and provide
physicians with rapid, reliable results. "AcQtrac ICG is a
non-invasive cardiovascular diagnostic system that provides the
hemodynamic information required to better assess and direct the
treatment of advanced heart failure, hypertension and other
cardiovascular diseases. The AcQtrac ICG is unique in its class
since it provides a waveform 'image' of the heart that serves as a
diagnostic aid and helpful tool in guiding drug therapy
management," said Paulita LaPlante, President vasamed.
"Cardiovascular disease is the nation's number one cause of death.
Two out of three people with diabetes die of cardiovascular
disease. As a woman, I am particularly focused on the tragedy that
more women die of cardiovascular disease annually than they do from
breast cancer. In fact more women than men in the U.S. die of heart
disease and stroke. Research shows that it is more difficult to
diagnose cardiovascular disease in women and we at vasamed want to
be part of the medical strategies and solutions that improve
outcomes for women as well as all patients." AcQtrac ICG System has
generated great interest in Heart Failure Clinics, Private Office
Cardiology, Critical Care Monitoring, Emergency Departments and
Pediatric Cardiology. AcQtrac ICG is a welcome addition to many
practices because non-invasive monitors are safer, more efficient
and cost-effective to use than invasive counterparts. About
vasamed. vasamed designs, licenses, manufactures and distributes
products that can be used by your doctor -- right in the office --
to determine if heart and blood vessels are healthy. vasamed's
products and technology include SensiLase(TM) Microvascular
Assessment System to monitor small blood vessel health, AcQtrac(TM)
Impedance Cardiography (ICG) to monitor heart function and Tissue
Carbon Dioxide Technologies to monitor tissue wellness. For more
information about vasamed technology and services and new products,
please call (800) 695.2737 or see the company's web site at
http://www.vasamed.com/ . DATASOURCE: vasamed CONTACT: Wes
Peterson, CFO of vasamed, +1-952-944-5857 ext. 542 Web site:
http://www.vasamed.com/
Copyright